{
    "info": {
        "nct_id": "NCT05672095",
        "official_title": "Phase I/II Trial of Niraparib/Selenium Combination Treatment in Patients With BRCA1/2-Wild Type Recurrent Platinum-Resistant Ovarian Cancer",
        "inclusion_criteria": "* Documented informed consent of the participant and/or legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* Agreement to allow the use of archival tissue from biopsy or tissue block cytology obtained at time of last disease recurrence. If biopsy is not possible or patient refuses, the principal investigator (PI) may allow an earlier biopsy to be tested. If unavailable, exceptions may be granted with Study PI approval\n* Age: >= 18 years\n* Eastern cooperative oncology group (ECOG) =< 2\n* Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer. May not have non epithelial tumors or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors or small cell carcinoma tumors or low grade serous carcinoma\n* Recurrent, platinum resistant disease (defined as progression within <6 months from completion of platinum-based therapy. The date should be calculated from the last administered dose of platinum therapy)\n* Measurable disease per response evaluation criteria in solid tumors (RECIST) 1.1 or evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease related in the setting of CA125 >2x upper limit of normal [ULN])\n* No more than 4 prior cytotoxic regimens (including primary therapy). Hormonal therapies (tamoxifen, aromatase inhibitors) or other prior poly (ADP-Ribose) polymerase (PARP) inhibitors will not count toward the prior regimen limit. Prior PARP inhibotor therapy is allowed\n* Fully recovered from the acute toxic effects (except alopecia) to =< Grade 1 to prior anti-cancer therapy\n* MyChoice HRD test should show BRCA wt and no HRD. No deleterious germline BRCA 1/2 mutations are allowed\n* Absolute neutrophil count (ANC) >= 1,500/mm^3 (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Platelets >= 150,000/mm^3 (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Total bilirubin =< 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease, when =< 2.0 X ULN is acceptable (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Aspartate aminotransferase (AST) =< 2.5 x ULN, unless liver metastases are present, in which case =< 5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Alanine aminotransferase (ALT) =< 2.5 x ULN, unless liver metastases are present, in which case =< 5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Serum Creatinine =< 1.5 x ULN or creatine clearance of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Prothrombin (PT) =< 1.25 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Hemoglobin >= 9 g/dL (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Women of childbearing potential (WOCBP): negative highly sensitive urine or serum pregnancy test (highly sensitive urine test will be required if serum pregnancy test is not available) (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Normal blood pressure or adequately controlled hypertension (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Agreement by subjects of childbearing potential* to use a highly effective method of birth control or abstain from heterosexual activity for the course of the study through at least 180 days after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Chemotherapy, biological therapy, immunotherapy within 21 days prior to Day 1 of protocol\n* Radiation therapy encompassing > 20% of the bone marrow within 2 weeks. Any radiation therapy within 1 week prior to Day 1 therapy\n* Colony-stimulating factors (e.g. granulocyte colony-stimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin within 4 weeks prior to day 1\n* Receipt of a transfusion (platelets or red blood cells) within 4 weeks of D1\n* Known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment\n* Diagnosis, detection, or treatment of another type of cancer ≤ 2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer in situ that has been definitively treated\n* Strong CYP3A4 inducers/ inhibitors within 14 days prior to Day 1 of protocol therapy\n* UGT1A1 inhibitors within 14 days prior to Day 1 of protocol therapy\n* Herbal medications containing selenium within 14 days prior to Day 1 of protocol therapy\n* Vitamin E within 14 days prior to Day 1 of protocol therapy\n* Anticoagulants within 14 days prior to Day 1 of protocol therapy or active thromboembolism. The use of ASA or NSAIDS is allowed\n* Live vaccines within 14 days prior to the first dose of study treatment. Seasonal flu vaccines that do not contain live viruses are allowed. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacille Calmette Guerin, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed. Intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines and are not allowed\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition (including aluminum) to study agent\n* Hypersensitivity to any study agent, or its excipients, when administered alone\n* History of Posterior Reversible Encephalopathy Syndrome (PRES)\n* Issues with tolerating oral medication (e.g. inability to swallow pills, malabsorption issues, ongoing nausea or vomiting)\n* Active diarrhea\n* Clinically significant uncontrolled illness or medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric order that prohibits obtaining informed consent\n* Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection\n* Other active malignancy\n* Females only: Pregnant or breastfeeding\n* Major surgery (other than debulking or exploratory surgery for ovarian cancer) for any reason within 3 weeks prior to randomization and/or incomplete recovery from surgery\n* Prior organ transplantation including allogenic stem cell transplantation\n* Diagnosis of Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)\n* Known leptomeningeal disease, carcinomatous meningitis, or radiologic signs of CNS hemorrhage. Known symptomatic brain metastases requiring steroids. Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study enrollment, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable\n* Active infections\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Patients must not have uncontrolled hypertension as defined by systolic blood pressure (SBP) >= 160mmHg or diastolic blood pressure (DBP) >= 90mmHg; patients whose blood pressure can be controlled medically are allowed to be rescreened once BP is under control\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Prothrombin (PT) =< 1.25 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Prothrombin (PT) =< 1.25 x ULN",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.25,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1,500/mm^3 (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1,500/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 150,000/mm^3 (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 150,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 150000,
                                "unit": "per mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern cooperative oncology group (ECOG) =< 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern cooperative oncology group (ECOG) =< 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum Creatinine =< 1.5 x ULN or creatine clearance of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Serum Creatinine =< 1.5 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatine clearance of >= 60 mL/min per 24 hour urine test",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "the Cockcroft-Gault formula (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
                    "criterion": "Cockcroft-Gault formula measurement",
                    "requirements": [
                        {
                            "requirement_type": "performed_within_days",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* MyChoice HRD test should show BRCA wt and no HRD. No deleterious germline BRCA 1/2 mutations are allowed",
            "criterions": [
                {
                    "exact_snippets": "MyChoice HRD test should show BRCA wt",
                    "criterion": "BRCA status (by MyChoice HRD test)",
                    "requirements": [
                        {
                            "requirement_type": "wild type",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "MyChoice HRD test should show ... no HRD",
                    "criterion": "homologous recombination deficiency (HRD) status (by MyChoice HRD test)",
                    "requirements": [
                        {
                            "requirement_type": "HRD negative",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "No deleterious germline BRCA 1/2 mutations are allowed",
                    "criterion": "germline BRCA 1/2 mutation status",
                    "requirements": [
                        {
                            "requirement_type": "deleterious mutation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer. May not have non epithelial tumors or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors or small cell carcinoma tumors or low grade serous carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cancer type",
                            "expected_value": [
                                "epithelial ovarian cancer",
                                "epithelial fallopian tube cancer",
                                "epithelial primary peritoneal cancer"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "May not have non epithelial tumors",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "non epithelial tumors"
                        }
                    ]
                },
                {
                    "exact_snippets": "May not have ... ovarian tumors with low malignant potential (ie, borderline tumors)",
                    "criterion": "tumor malignant potential",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "ovarian tumors with low malignant potential (borderline tumors)"
                        }
                    ]
                },
                {
                    "exact_snippets": "May not have ... mucinous tumors",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "mucinous tumors"
                        }
                    ]
                },
                {
                    "exact_snippets": "May not have ... small cell carcinoma tumors",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "small cell carcinoma tumors"
                        }
                    ]
                },
                {
                    "exact_snippets": "May not have ... low grade serous carcinoma",
                    "criterion": "tumor grade and histology",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "low grade serous carcinoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No more than 4 prior cytotoxic regimens (including primary therapy). Hormonal therapies (tamoxifen, aromatase inhibitors) or other prior poly (ADP-Ribose) polymerase (PARP) inhibitors will not count toward the prior regimen limit. Prior PARP inhibotor therapy is allowed",
            "criterions": [
                {
                    "exact_snippets": "No more than 4 prior cytotoxic regimens (including primary therapy)",
                    "criterion": "number of prior cytotoxic regimens",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "regimens"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Hormonal therapies (tamoxifen, aromatase inhibitors) or other prior poly (ADP-Ribose) polymerase (PARP) inhibitors will not count toward the prior regimen limit",
                    "criterion": "prior hormonal therapy or prior PARP inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "counted toward prior regimen limit",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior PARP inhibotor therapy is allowed",
                    "criterion": "prior PARP inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agreement by subjects of childbearing potential* to use a highly effective method of birth control or abstain from heterosexual activity for the course of the study through at least 180 days after the last dose of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "subjects of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Agreement by subjects ... to use a highly effective method of birth control or abstain from heterosexual activity for the course of the study through at least 180 days after the last dose of protocol therapy",
                    "criterion": "contraception or abstinence",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use birth control or abstain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease, when =< 2.0 X ULN is acceptable (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 X upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless has Gilbert's disease, when =< 2.0 X ULN is acceptable",
                    "criterion": "total bilirubin in patients with Gilbert's disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "X ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age: >= 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age: >= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)",
            "criterions": [
                {
                    "exact_snippets": "not being surgically sterilized (men and women)",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have not been free from menses for > 1 year (women only)",
                    "criterion": "menstrual status (women only)",
                    "requirements": [
                        {
                            "requirement_type": "time since last menses",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Assent, when appropriate, will be obtained per institutional guidelines",
            "criterions": [
                {
                    "exact_snippets": "Assent, when appropriate, will be obtained per institutional guidelines",
                    "criterion": "assent",
                    "requirements": [
                        {
                            "requirement_type": "obtained",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "per institutional guidelines",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential (WOCBP): negative highly sensitive urine or serum pregnancy test (highly sensitive urine test will be required if serum pregnancy test is not available) (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP)",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative highly sensitive urine or serum pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "performed within 14 days prior to day 1 of protocol therapy",
                    "criterion": "timing of pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "time before protocol therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Normal blood pressure or adequately controlled hypertension (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Normal blood pressure or adequately controlled hypertension",
                    "criterion": "blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "normal",
                                "adequately controlled hypertension"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "performed within 14 days prior to day 1 of protocol therapy",
                    "criterion": "blood pressure assessment timing",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agreement to allow the use of archival tissue from biopsy or tissue block cytology obtained at time of last disease recurrence. If biopsy is not possible or patient refuses, the principal investigator (PI) may allow an earlier biopsy to be tested. If unavailable, exceptions may be granted with Study PI approval",
            "criterions": [
                {
                    "exact_snippets": "Agreement to allow the use of archival tissue from biopsy or tissue block cytology obtained at time of last disease recurrence",
                    "criterion": "archival tissue from biopsy or tissue block cytology",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained at time of last disease recurrence"
                        }
                    ]
                },
                {
                    "exact_snippets": "If biopsy is not possible or patient refuses, the principal investigator (PI) may allow an earlier biopsy to be tested",
                    "criterion": "earlier biopsy tissue",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "earlier than last disease recurrence"
                        },
                        {
                            "requirement_type": "approval",
                            "expected_value": "principal investigator"
                        }
                    ]
                },
                {
                    "exact_snippets": "If unavailable, exceptions may be granted with Study PI approval",
                    "criterion": "archival or earlier biopsy tissue",
                    "requirements": [
                        {
                            "requirement_type": "exception_approval",
                            "expected_value": "Study PI"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) =< 2.5 x ULN, unless liver metastases are present, in which case =< 5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) =< 2.5 x ULN, unless liver metastases are present, in which case =< 5 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if liver metastases are present)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recurrent, platinum resistant disease (defined as progression within <6 months from completion of platinum-based therapy. The date should be calculated from the last administered dose of platinum therapy)",
            "criterions": [
                {
                    "exact_snippets": "Recurrent, platinum resistant disease",
                    "criterion": "disease recurrence and platinum resistance",
                    "requirements": [
                        {
                            "requirement_type": "recurrence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "platinum resistance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "progression within <6 months from completion of platinum-based therapy",
                    "criterion": "progression-free interval after platinum-based therapy",
                    "requirements": [
                        {
                            "requirement_type": "time to progression",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented informed consent of the participant and/or legally authorized representative",
            "criterions": [
                {
                    "exact_snippets": "Documented informed consent of the participant",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": "participant"
                        }
                    ]
                },
                {
                    "exact_snippets": "and/or legally authorized representative",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": "legally authorized representative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9 g/dL (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fully recovered from the acute toxic effects (except alopecia) to =< Grade 1 to prior anti-cancer therapy",
            "criterions": [
                {
                    "exact_snippets": "Fully recovered from the acute toxic effects (except alopecia) to =< Grade 1 to prior anti-cancer therapy",
                    "criterion": "acute toxic effects from prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "(except alopecia)",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) =< 2.5 x ULN, unless liver metastases are present, in which case =< 5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) =< 2.5 x ULN, unless liver metastases are present, in which case =< 5 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if liver metastases present)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "performed within 14 days prior to day 1 of protocol therapy",
                    "criterion": "ALT test timing",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 14 days prior to day 1 of protocol therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease per response evaluation criteria in solid tumors (RECIST) 1.1 or evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease related in the setting of CA125 >2x upper limit of normal [ULN])",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per response evaluation criteria in solid tumors (RECIST) 1.1",
                    "criterion": "measurable disease (RECIST 1.1)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions",
                    "criterion": "evaluable disease (non-RECIST solid/cystic abnormalities)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ascites and/or pleural effusion that has been pathologically demonstrated to be disease related",
                    "criterion": "ascites or pleural effusion (disease-related, pathologically demonstrated)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease-related (pathologically demonstrated)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CA125 >2x upper limit of normal [ULN]",
                    "criterion": "CA125 level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Diagnosis, detection, or treatment of another type of cancer ≤ 2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer in situ that has been definitively treated",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis, detection, or treatment of another type of cancer ≤ 2 years prior to initiating protocol therapy",
                    "criterion": "history of another type of cancer",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis, detection, or treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except basal or squamous cell carcinoma of the skin and cervical cancer in situ that has been definitively treated",
                    "criterion": "history of basal or squamous cell carcinoma of the skin or cervical cancer in situ",
                    "requirements": [
                        {
                            "requirement_type": "definitive treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Strong CYP3A4 inducers/ inhibitors within 14 days prior to Day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Strong CYP3A4 inducers/ inhibitors within 14 days prior to Day 1 of protocol therapy",
                    "criterion": "use of strong CYP3A4 inducers or inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to Day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hypersensitivity to any study agent, or its excipients, when administered alone",
            "criterions": [
                {
                    "exact_snippets": "Hypersensitivity to any study agent, or its excipients, when administered alone",
                    "criterion": "hypersensitivity to study agent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hypersensitivity to any study agent, or its excipients, when administered alone",
                    "criterion": "hypersensitivity to excipients of study agent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Live vaccines within 14 days prior to the first dose of study treatment. Seasonal flu vaccines that do not contain live viruses are allowed. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacille Calmette Guerin, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed. Intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines and are not allowed",
            "criterions": [
                {
                    "exact_snippets": "Live vaccines within 14 days prior to the first dose of study treatment",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Seasonal flu vaccines that do not contain live viruses are allowed",
                    "criterion": "seasonal flu vaccine (non-live) administration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines and are not allowed",
                    "criterion": "intranasal influenza vaccine (live attenuated) administration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other active malignancy",
            "criterions": [
                {
                    "exact_snippets": "Other active malignancy",
                    "criterion": "active malignancy (other than index cancer)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receipt of a transfusion (platelets or red blood cells) within 4 weeks of D1",
            "criterions": [
                {
                    "exact_snippets": "Receipt of a transfusion (platelets or red blood cells) within 4 weeks of D1",
                    "criterion": "transfusion (platelets or red blood cells)",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "platelets",
                                "red blood cells"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infections",
            "criterions": [
                {
                    "exact_snippets": "Active infections",
                    "criterion": "infections",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Colony-stimulating factors (e.g. granulocyte colony-stimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin within 4 weeks prior to day 1",
            "criterions": [
                {
                    "exact_snippets": "Colony-stimulating factors (e.g. granulocyte colony-stimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin within 4 weeks prior to day 1",
                    "criterion": "colony-stimulating factor use",
                    "requirements": [
                        {
                            "requirement_type": "use within prior period",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment",
            "criterions": [
                {
                    "exact_snippets": "Known Grade 3 or 4 anemia",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "prior chemotherapy"
                        },
                        {
                            "requirement_type": "persistence_duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relation_to_treatment",
                            "expected_value": "most recent treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Known Grade 3 or 4 ... neutropenia",
                    "criterion": "neutropenia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "prior chemotherapy"
                        },
                        {
                            "requirement_type": "persistence_duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relation_to_treatment",
                            "expected_value": "most recent treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Known Grade 3 or 4 ... thrombocytopenia",
                    "criterion": "thrombocytopenia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "prior chemotherapy"
                        },
                        {
                            "requirement_type": "persistence_duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relation_to_treatment",
                            "expected_value": "most recent treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant uncontrolled illness or medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric order that prohibits obtaining informed consent",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant uncontrolled illness or medical disorder",
                    "criterion": "illness or medical disorder",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "nonmalignant systemic disease",
                    "criterion": "systemic disease",
                    "requirements": [
                        {
                            "requirement_type": "malignancy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active, uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled ventricular arrhythmia",
                    "criterion": "ventricular arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "recent (90 days) myocardial infarction",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled major seizure disorder",
                    "criterion": "major seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable spinal cord compression",
                    "criterion": "spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "superior vena cava syndrome",
                    "criterion": "superior vena cava syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any psychiatric order that prohibits obtaining informed consent",
                    "criterion": "psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "effect on consent",
                            "expected_value": "prohibits obtaining informed consent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of Posterior Reversible Encephalopathy Syndrome (PRES)",
            "criterions": [
                {
                    "exact_snippets": "History of Posterior Reversible Encephalopathy Syndrome (PRES)",
                    "criterion": "Posterior Reversible Encephalopathy Syndrome (PRES)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition (including aluminum) to study agent",
            "criterions": [
                {
                    "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition (including aluminum) to study agent",
                    "criterion": "allergic reactions to compounds of similar chemical or biologic composition to study agent",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiation therapy encompassing > 20% of the bone marrow within 2 weeks. Any radiation therapy within 1 week prior to Day 1 therapy",
            "criterions": [
                {
                    "exact_snippets": "Radiation therapy encompassing > 20% of the bone marrow within 2 weeks",
                    "criterion": "radiation therapy to bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "coverage",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "time since radiation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Any radiation therapy within 1 week prior to Day 1 therapy",
                    "criterion": "any radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since radiation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known leptomeningeal disease, carcinomatous meningitis, or radiologic signs of CNS hemorrhage. Known symptomatic brain metastases requiring steroids. Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study enrollment, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable",
            "criterions": [
                {
                    "exact_snippets": "Known leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "radiologic signs of CNS hemorrhage",
                    "criterion": "CNS hemorrhage (radiologic signs)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Known symptomatic brain metastases requiring steroids",
                    "criterion": "symptomatic brain metastases requiring steroids",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study enrollment",
                    "criterion": "previously diagnosed brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recovery from acute effects of radiation therapy or surgery",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have discontinued corticosteroid treatment for these metastases for at least 4 weeks",
                    "criterion": "corticosteroid treatment for brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "are neurologically stable",
                    "criterion": "neurological stability",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Herbal medications containing selenium within 14 days prior to Day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Herbal medications containing selenium within 14 days prior to Day 1 of protocol therapy",
                    "criterion": "herbal medication containing selenium",
                    "requirements": [
                        {
                            "requirement_type": "use within prior days",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to Day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* UGT1A1 inhibitors within 14 days prior to Day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "UGT1A1 inhibitors within 14 days prior to Day 1 of protocol therapy",
                    "criterion": "UGT1A1 inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to Day 1 of protocol therapy"
                            }
                        },
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection",
            "criterions": [
                {
                    "exact_snippets": "Known history of immunodeficiency virus (HIV)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Vitamin E within 14 days prior to Day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Vitamin E within 14 days prior to Day 1 of protocol therapy",
                    "criterion": "Vitamin E use",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days prior to Day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Issues with tolerating oral medication (e.g. inability to swallow pills, malabsorption issues, ongoing nausea or vomiting)",
            "criterions": [
                {
                    "exact_snippets": "inability to swallow pills",
                    "criterion": "ability to swallow pills",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption issues",
                    "criterion": "malabsorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing nausea or vomiting",
                    "criterion": "ongoing nausea or vomiting",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of Myelodysplastic Syndrome (MDS)",
                    "criterion": "Myelodysplastic Syndrome (MDS) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... Acute Myeloid Leukemia (AML)",
                    "criterion": "Acute Myeloid Leukemia (AML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior organ transplantation including allogenic stem cell transplantation",
            "criterions": [
                {
                    "exact_snippets": "Prior organ transplantation",
                    "criterion": "organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including allogenic stem cell transplantation",
                    "criterion": "allogenic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
            "criterions": [
                {
                    "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                    "criterion": "ability to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator",
                    "criterion": "investigator's judgment of participant compliance",
                    "requirements": [
                        {
                            "requirement_type": "investigator assessment",
                            "expected_value": "satisfactory"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy, biological therapy, immunotherapy within 21 days prior to Day 1 of protocol",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy ... within 21 days prior to Day 1 of protocol",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "biological therapy ... within 21 days prior to Day 1 of protocol",
                    "criterion": "biological therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "immunotherapy within 21 days prior to Day 1 of protocol",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anticoagulants within 14 days prior to Day 1 of protocol therapy or active thromboembolism. The use of ASA or NSAIDS is allowed",
            "criterions": [
                {
                    "exact_snippets": "Anticoagulants within 14 days prior to Day 1 of protocol therapy",
                    "criterion": "anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active thromboembolism",
                    "criterion": "thromboembolism",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures",
            "criterions": [
                {
                    "exact_snippets": "Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures",
                    "criterion": "other condition contraindicating participation due to safety concerns",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "safety concern with clinical study procedures",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery (other than debulking or exploratory surgery for ovarian cancer) for any reason within 3 weeks prior to randomization and/or incomplete recovery from surgery",
            "criterions": [
                {
                    "exact_snippets": "Major surgery (other than debulking or exploratory surgery for ovarian cancer) for any reason within 3 weeks prior to randomization",
                    "criterion": "major surgery (excluding debulking or exploratory surgery for ovarian cancer)",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "incomplete recovery from surgery",
                    "criterion": "recovery from surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": "complete"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active diarrhea",
            "criterions": [
                {
                    "exact_snippets": "Active diarrhea",
                    "criterion": "diarrhea",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females only: Pregnant or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Females only",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have uncontrolled hypertension as defined by systolic blood pressure (SBP) >= 160mmHg or diastolic blood pressure (DBP) >= 90mmHg; patients whose blood pressure can be controlled medically are allowed to be rescreened once BP is under control",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled hypertension as defined by systolic blood pressure (SBP) >= 160mmHg or diastolic blood pressure (DBP) >= 90mmHg",
                    "criterion": "blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "systolic blood pressure",
                            "expected_value": {
                                "operator": "<",
                                "value": 160,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "diastolic blood pressure",
                            "expected_value": {
                                "operator": "<",
                                "value": 90,
                                "unit": "mmHg"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}